Amarillo Biosciences -- Report on Australian Oral Interferon Influenza Study Is Submitted and Available Online

AMARILLO, TX--(Marketwire - April 09, 2010) -

Highlighted Links

MacReport Media Publishing

Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences, The University of Western Australia, has submitted a final report on the recently completed 200 subject low-dose oral interferon (IFN) Phase 2 clinical trial in Perth, Australia. Dr. Beilharz was one of two principal investigators of the study for which ABI provided the oral interferon. The report, sent to the State Health Research Advisory Council of the Department of Health, Western Australia (DOH WA) evaluated the drug's safety and efficacy in combating colds and influenza. The report is available on ABI's website (http://www.amarbio.com/Download-document/20-Australian-Influenza-Study-Report.html).

In his report, Dr. Beilharz wrote, "The results of the study show that IFN lozenges can be used to significantly reduce the incidence and severity of respiratory symptoms reported by people over the age of 50 years. A 48% reduction in these symptoms was demonstrated in this study, with the potential to save the DOH WA $600,000 to $1.77 million dollars annually depending on the level of treatment uptake by the community. IFN prophylaxis was also found to enhance the effect of the 2009 seasonal influenza vaccine, causing a 39% reduction in the number of vaccinated participants reporting influenza-like illnesses. This was despite the fact that seasonal vaccine had previously been shown to be ineffective against the predominant circulating virus (pandemic influenza H1N1 2009)."

Dr. Beilharz commented further on the possible uses by broader segments of the population, "In addition, the recruitment process has shown there is a great interest from the wider community in the use of low dose interferon lozenges, particularly in relation to fears precipitated by the 2009 H1N1 pandemic. Therefore, in view of the good side effect profile of oral IFN, it could also be used by other community members who wish to reduce risk, though it is likely to require larger trials to define the benefits in those under 50."

Dr. Beilharz will report the findings at the 3rd World Summit of Antiviral Summit Shelf in Busan, South Korea on July 31-August 3, 2010 in a presentation titled, Low Dose Oral Type 1 IFN: A New Defense Against Colds and Flu.

Dr. Joseph Cummins, CEO of ABI, said, "If the use of low-dose oral interferon can save DOH WA millions of dollars as they serve a small population, the potential savings in the U.S. population are vastly greater. We are eager to conduct clinical trials in an effort to achieve FDA approval, to help reduce healthcare costs in the US."

About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures About Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2009.